Orthofix (OFIX) Q3 2026 earnings review
Orthofix cuts its annual outlook as US spine sales fall
Orthofix, a maker of spinal implants and bone-healing devices, cut its full-year targets after supply shortages and weak demand hit its core US spine business. Sales excluding discontinued artificial discs rose 2% from a year ago to $208 million, falling short of the company's prior plan to match the second quarter. Lower overhead and reduced employee bonus accruals lifted quarterly profit excluding one-offs, but chief executive Massimo Calafiore lowered the full-year outlook, which by our math points to sales shrinking almost 3% in the fourth quarter.
| Sales excluding discontinued M6 discs | $207.8M +2.2% from a year ago (+2.3% constant currency) |
|---|---|
| US Spine, Biologics & Enabling Tech sales | $92.8M -4.3% from a year ago |
| Adjusted EBITDA | $26.0M 12.5% of underlying sales vs 12.1% a year ago |
| Full-year sales outlook | Cut $22.5M middle of the range: $827.5M (+1.9% growth) |
⚖️ Verdict: 🔴 Bearish
The story got worse because operational trouble in US spine spread from smaller sales partners to the top distributors that generate 80% of spine fixation revenue. Supplier delays and a shortage of surgical instrument sets capped growth at those top partners, forcing another round of distributor restructuring that will weigh on fourth-quarter sales and cash flow. One bright spot: limb reconstruction and bone-healing therapies kept growing above their market rates after Medicare restored payment rates.
The question now is whether the US spine slump is a temporary supply bottleneck that reallocating surgical trays can fix, or a deeper loss of share from shrinking the distributor network. If the problem is just tray allocation, top-distributor growth will rebound once sets move and the Virata implant system launches; if it is structural, US spine sales will keep sliding into 2027. Fourth-quarter US spine revenue and the 2027 outlook will settle it.
🐂 Bull Case
Limb Reconstruction and Bone Therapies Carry Growth
"Continued growth in Limb Reconstruction and Therapeutic Solutions helped offset weaker Spine performance," chief executive Massimo Calafiore said. Therapeutic Solutions sells wearable devices that use electrical signals to heal bone fractures, while Limb Reconstruction sells metal frames and internal nails to lengthen or straighten bones. Both units beat the 2% to 6% growth rates Orthofix estimates for their broader markets.
- Global Limb Reconstruction sales: $36.4 million, up 8.5% (9.4% in constant currency)
- Therapeutic Solutions sales: $64.0 million, up 4.5% after Medicare restored payment rates
- International spine and biologics sales: $14.6 million, up 24.9% in constant currency
- Biologics (bone graft materials): continued to stabilize after shrinking last year
These businesses matter because they give the medical device maker a steady base while it restructures its US spine sales network. International demand and adoption of the TrueLok Elevate frame and Fitbone lengthening nail drove the limb unit, and Orthofix submitted an application to regulators for an automated TrueLok version. However, overseas sales carry lower gross margins, and international order timing still weighed on the full-year outlook.
What to watch: US Limb Reconstruction sales growth in the quarterly filing's geographic table. Management previously promised a return to double-digit US growth in the second half after three flat quarters.
Lower Overhead and Bonus Cuts Lifted Profit
Orthofix expanded its quarterly profit margin excluding one-offs even though sales barely grew and gross margin fell. Adjusted EBITDA — earnings before interest, taxes, depreciation, amortization and one-time items — rose 5.9% from a year ago to $26.0 million, or 12.5% of underlying sales compared with 12.1% a year earlier.
Selling and overhead expenses did the work. Excluding one-offs, those costs fell 2.4 percentage points to 59.0% of underlying sales, which more than covered a 1.4-point drop in gross margin caused by higher international mix. On a reported basis, operating profit flipped from a $17.0 million loss to a $1.5 million profit, mainly because legal costs dropped by $21.2 million from last year's heavy arbitration expenses.
The catch is how the Texas-based group achieved the savings. In its presentation, Orthofix attributed the profit support to "Continued cost discipline, reduced incentive compensation and ongoing resource-allocation actions". Cutting employee bonuses because the company missed its own annual targets is an automatic cushion, not a repeatable efficiency gain.
What to watch: selling and overhead expenses as a share of sales in the fourth quarter. A rise back above 60% would show that Q3's margin gain relied on reversing bonus accruals rather than permanent cost cuts.
🐻 Bear Case
US Spine Trouble Spreads to Top Distributors
For three quarters, Calafiore argued that Orthofix's US spine problems sat in the bottom 20% of its sales network while the top 30 distributors — who generate about 80% of spine fixation sales — performed well. This quarter, the trouble reached the top tier. US sales of spinal implants, biologics and navigation systems fell 4.3% from a year ago to $92.8 million, worsening from a 1.0% dip in Q2.
In its presentation, Orthofix admitted that "market softness, unplanned supplier delays and inventory and instrument set constraints limited growth among our largest distributors, while smaller distributors continued to underperform". In other words, the company ran short of surgical trays and parts for the very partners it relies on to carry the business. Calafiore said the group is now "accelerating actions to strengthen commercial execution, improve instrument set supply and allocation, and increase asset productivity".
This matters because the spine channel overhaul — which management called complete in late 2025 — is now disrupting fourth-quarter sales too. Pulling surgical sets from smaller distributors and reallocating them to top partners will depress revenue in the near term before any productivity gain appears, and Orthofix still awaits the full US launch of its Virata spinal fixation system later in Q4.
What to watch: US spinal implants, biologics and enabling technologies growth in Q4. A second straight decline near 4% after Virata launches would show that distributor churn is costing Orthofix market share.
Outlook Cut Points to a Q4 Contraction
Orthofix cut its full-year outlook for sales excluding discontinued M6 artificial discs by $22.5 million at the middle of the range, to $825–830 million, and lowered its adjusted EBITDA target by $9.5 million, to $86–88 million. Just three months ago, management had raised both targets on a planned $15 million bulk inventory sale to a European distributor ahead of new medical device rules.
- Full-year underlying sales growth at the middle of the range: 1.9% by our math, down from ~5% previously
- Implied Q4 underlying sales: $212.4 million by our math, down 2.8% from $218.6 million a year ago
- Implied Q4 adjusted EBITDA: $31.1 million by our math, a 14.7% margin vs 12.5% in Q3
- Reasons cited for the sales cut: Q3 results, spine market softness, US spine actions, "the timing of international Limb Reconstruction orders and foreign-exchange headwinds"
The cut confirms that the previous second-half plan was out of reach. By our math, the new forecast has fourth-quarter underlying sales shrinking almost 3% from a year ago, even though Q4 was supposed to include the majority of the $15 million European pre-buy. Worse, any international orders that slip out of Q4 or any European pre-buy that does land still leave 2027 facing a stated $22 million European regulatory headwind.
What to watch: how much revenue from the European distributor arrangement Orthofix records in Q4. If the company needed that one-time pre-buy just to hit its lowered $212.4 million implied Q4 target, underlying demand shrank even faster.
Cash Burn Continues as Inventory Builds
Orthofix prioritizes positive free cash flow in its investor presentation, but the business burned cash again in the third quarter. For the first nine months of 2026, free cash flow — operating cash flow minus capital spending — was an outflow of $61.3 million, more than triple the $18.1 million outflow in the same period last year.
By our math, subtracting the first half's $47.1 million outflow leaves a $14.1 million free cash outflow in Q3 alone, compared with positive $2.5 million in Q3 last year. Operating cash flow was roughly breakeven at $0.4 million by our math, while capital spending consumed $14.5 million as the company bought surgical instrument sets. Cash including restricted cash fell by $17.5 million during the quarter to $86.9 million, which the release blamed on working capital timing, while inventories climbed to $190.4 million, up 10.5% since December.
What to watch: fourth-quarter free cash flow and inventory levels at year-end. Management withdrew its full-year positive free cash flow target last quarter, and a Q4 inflow will require working down that $190.4 million inventory pile.
Risks this quarter didn't answer
Several standing concerns from prior quarters received no new numbers in the third-quarter earnings release or investor presentation.
- Multi-year financial targets: the 2026–2028 plan (6.5–7.5% annual sales growth and mid-teens adjusted EBITDA margin) remains absent from the presentation after management stepped back from it in Q2.
- Top-30 US spine distributor growth: omitted for a second straight quarter after running at 25–27% through Q1; the presentation states only that supply constraints limited their growth.
- Standalone Biologics sales and 7D Flash navigation placements: neither figure appears in the release; the quarterly filing's footnotes and conference call are the next disclosure points.
- Distributor buyout options and shareholder lawsuits: no update in the release on the distributor exercising its buyout option or pending securities litigation; the 10-Q legal and commitments footnotes will carry the update.
💲 Other KPIs
Fell 1.4 percentage points from 72.1% of underlying sales a year ago, and stepped down from 71.7% in Q2. Orthofix attributed the decline to geographic mix, as lower-margin international sales grew faster than US sales. That move runs against management's prior multi-year goal of expanding gross margin by 3 percentage points.
Increased by $17.8 million from $130.2 million at the end of Q2 by our math, as total debt and finance leases held steady at $234.9 million while cash dropped to $86.9 million. Net interest expense rose 25.8% from a year ago to $5.9 million after the group drew $65 million on its term loan in January.
Rose 3.5% from 39.8 million shares a year ago and ticked up from 40.9 million in Q2. Orthofix does not repurchase shares and funds employee compensation and certain distributor agreements with stock, gradually diluting existing holders.
🔮 Guidance
Cut. The middle of the range fell by $22.5 million, lowering full-year underlying growth to 1.9% by our math, down from about 5% previously. By our math, that leaves $212.4 million for Q4, a 2.8% drop from a year ago. It is the second cut in four quarters: $0M, -$12M, +$7M, and now -$22.5M, driven by US spine delays, distributor restructuring and international order timing.
Cut. Management lowered the middle of the range by $9.5 million, leaving full-year profit excluding one-offs up just 1.3% from $85.9 million in 2025 by our math. With $55.9 million earned in the first nine months, the plan requires $31.1 million in Q4 by our math, or a 14.7% margin against 12.5% in Q3. Across four updates, the midpoint moved $0M, -$5M, +$5M, and -$9.5M.
❓ Key Questions
How much did the top 30 US spine distributors grow?
Orthofix reported 25% to 27% growth for its top 30 US spine partners through Q1, stopped giving the number in Q2, and now says supplier delays and tray shortages limited their growth in Q3. Without the rate, investors cannot separate supply hiccups from lost surgeon demand.
Is the $15 million European inventory pre-buy still in Q4?
Last quarter's raise relied on a $15 million bulk sale to a European distributor ahead of regulatory changes, mostly in Q4. The Q3 cut cites international limb reconstruction order timing, leaving unclear how much one-time European revenue remains in the implied $212.4 million Q4 target.
What was US Limb Reconstruction growth in the third quarter?
Global Limb Reconstruction grew 9.4% in constant currency, but the presentation attributes that to international demand. US growth was just 1.6% in Q2, and management previously promised a second-half return to double-digit US growth.
How much revenue will the US spine distributor overhaul cost?
Management is pulling surgical sets and resources toward its highest-performing distributors after declaring the channel transition largely behind it earlier this year. Investors need to know how many smaller distributors are being exited and when the revenue drag ends.